News

The European Society of Cataract and Refractive Surgeons (ESCRS) never fails to entice ophthalmology with cutting-edge technology, and the XXXII Congress in London has not disappointed attendees. This year’s congress has displayed a wide range of new technologies from cataract and refractive platforms to diagnostic units to surgical instruments. From all the equipment presented, IOL advances have again captured the attention of attendees.

In retrospect-even though Army life was not for me-going to France was a unique opportunity for a young man to gain perspective on the culture of Western Europe. With my 2-year “vacation” at an end, I was ready to focus on my future in ophthalmology.

Analyses of data from the Inhibition of VEGF in Age-related Choroidal Neovascularisation trial conducted to explore relationships between temporal changes in serum VEGF and safety events showed that at 1 year, a larger fall from baseline serum VEGF was associated with a lower hazard of death.

The self-pay, lifestyle health care market is poised for huge growth as the population of the United States ages. A new cooperative offers a host of tools and services to help board-certified ophthalmologists capitalize on opportunities in the self-pay market.

Practices with an offering of specialty eyewear-and with the knowledge for how to promote these products-not only will reap benefits for patients but also for the clinic financially.

Avedro has purchased the assets of IROC Innocross, a Swish company that has commercialized a cross-linking device for the treatment of keratoconus and other corneal pathologies.

Beaver-Visitec has announced the purchase of Endo Optiks, a company that focuses on the treatment of glaucoma and retinal diseases via minimally invasive endoscopy.

Dosing has commenced for the first patients enrolled in Aerie Pharmaceuticals’ phase III registration trial in Canada of Rhopressa, a novel once-daily, triple-action eye drop being tested for its ability to lower IOP in patients with glaucoma or ocular hypertension.

The Swedish Medical Products Agency has granted marketing authorization of Alimera Sciences’ Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

William Fredette, MD, discusse the results of two trials published in Opthalmology, which indicate that the combination of Verteporfin Photodynamic Therapy plus ranibizumab injections is no better than ranibizumab alone for treating subfoveal choroidal neovascularization secondary to AMD. Video provided by The Doctor's Channel.

Understanding the magnitude of patients with poor vision in a hospital setting is crucial in developing interventions that potentially limit vision-related morbidity, such as falls, said Jeffrey R. Willis, MD, PhD.